Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jazz Pharmaceuticals PLC reaffirms FY 2014 guidance

Thursday, 8 May 2014 04:10pm EDT 

Jazz Pharmaceuticals PLC:Continues to expect FY 2014 revenues of $1.100-$1.160 bln.FY 2014 GAAP net income per diluted share of $1.81-$2.30.FY 2014 Non-GAAP Adjusted Net Income Per Diluted Share of $8.00-$8.25.FY 2014 revenue of $1.135 bln and EPS of $8.20 - Thomson Reuters I/B/E/S. 

Company Quote

-3.91 -2.18%
26 Feb 2015